• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Ruben Mesa Outlines the Quality-of-Life Impact of Myelofibrosis

Video

Patients with myelofibrosis can see their quality of life impacted in a range of ways with various symptoms, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.

Patients with myelofibrosis can see their quality of life impacted in a range of ways with various symptoms, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.

Transcript

What is the quality of life like for patients with myelofibrosis? How does it negatively impact them?

Quality of life in patients with myelofibrosis is really impacted in a range of ways. You know, first, they can have a degree of cytopenia-related difficulties. With anemia, they can have shortness of breath, fatigue, they can have thrombocytopenia, have increased risk of bruising, bleeding, etc.

Second, there's a whole range of what we believe are cytokine-related symptoms that they have from the disease. That can be inadvertent weight loss, night sweats, cachexia itching, things of that nature.

Third, if the counter high they can have vascular-related side effects: difficulties with headaches, concentration, complex migraines, etc.

Next, they may have potentially difficulties related to their spleen issues. Patients can sometimes have massive splenomegaly and with that they can have early satiety, they can kind of worse in that disease-associated weight loss, or they can have pain, discomfort, and derivative to these, they can have a lot of difficulties with insomnia and things of that nature.

It's really a whole range of things. Overall, we find that almost 90% of patients with myelofibrosis are symptomatic from their disease, some of them in a very severe way. And the individual pattern of symptoms is obviously somewhat unique to each patient.

Related Videos
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.